PA8744101A1 - Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia - Google Patents

Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia

Info

Publication number
PA8744101A1
PA8744101A1 PA20078744101A PA8744101A PA8744101A1 PA 8744101 A1 PA8744101 A1 PA 8744101A1 PA 20078744101 A PA20078744101 A PA 20078744101A PA 8744101 A PA8744101 A PA 8744101A PA 8744101 A1 PA8744101 A1 PA 8744101A1
Authority
PA
Panama
Prior art keywords
therapy
hepatitis
treatment
infection
virus
Prior art date
Application number
PA20078744101A
Other languages
English (en)
Inventor
Y M Howe Anita
Villano Stephen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8744101A1 publication Critical patent/PA8744101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODOS DE TERAPIA COMBINADA PARA EL TRATAMIENTO DE LA INFECCIÓN CAUSADA POR EL VIRUS DE LA HEPATITIS C Y ENFERMEDADES RELACIONADAS, MEDIANTE LA ADMINISTRACIÓN CONJUNTA DE METILAMIDA DEL ÁCIDO 5-CICLOPROPIL-2-(4- FLUORO-FENIL)-6-[(2-HIDROXI-ETIL)-METANSULFONIL-AMINO]-BENZOFURAN-3CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, CON INTERFERÓN NATURAL, RECOMBINANTE O MODIFICADO, QUE INHIBE EN FORMA EFICAZ LA REPLICACIÓN VIRAL.
PA20078744101A 2006-08-25 2007-08-23 Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia PA8744101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84008506P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
PA8744101A1 true PA8744101A1 (es) 2009-04-23

Family

ID=39107638

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078744101A PA8744101A1 (es) 2006-08-25 2007-08-23 Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia

Country Status (7)

Country Link
US (1) US20080075695A1 (es)
AR (1) AR062453A1 (es)
CL (1) CL2007002490A1 (es)
PA (1) PA8744101A1 (es)
PE (1) PE20080612A1 (es)
TW (1) TW200815384A (es)
WO (1) WO2008024843A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024763A2 (en) * 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
BR112020004611A2 (pt) 2017-09-12 2020-09-24 Jiangsu Hengrui Medicine Co., Ltd. derivado de indol formamida substituído por átomo de deutério, método de preparação do mesmo e aplicações médicas do mesmo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2003000348A (es) * 2002-11-01 2008-10-14 Viropharma Inc Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
PT1835951E (pt) * 2004-12-20 2011-05-02 Tibotec Pharm Ltd Inibidor de vhc para utiliza??o num m?todo de tratamento da hepatite c
CA2597213A1 (en) * 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections

Also Published As

Publication number Publication date
CL2007002490A1 (es) 2008-03-07
WO2008024843A2 (en) 2008-02-28
US20080075695A1 (en) 2008-03-27
TW200815384A (en) 2008-04-01
WO2008024843A3 (en) 2008-10-30
AR062453A1 (es) 2008-11-12
PE20080612A1 (es) 2008-07-23

Similar Documents

Publication Publication Date Title
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
JP2010503396A5 (es)
NI200900205A (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c.
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
MY169275A (en) Method of immunization against the four serotypes of dengue
EA201991174A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
RU2015114543A (ru) Способы лечения гепатита с
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
MX2012004409A (es) Proteina recombinante de humano cc10 para el tratamiento de la influenza.
MX2021015003A (es) Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
WO2010138419A3 (en) Materials and methods for treating viral infections
BR112023014825A2 (pt) Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto a
MD3121F1 (en) Method of viral hepatitis B prophylaxis